These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8195034)

  • 21. Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake.
    Skarsgard LD; Acheson DK; Vinczan A; Wouters BG; Heinrichs BE; Loblaw DA; Minchinton AI; Chaplin DJ
    Br J Cancer; 1995 Dec; 72(6):1479-86. PubMed ID: 8519663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioreductive drugs: from concept to clinic.
    McKeown SR; Cowen RL; Williams KJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E; Stern S; Guichard M
    Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
    Stern S; Guichard M
    Radiother Oncol; 1996 Nov; 41(2):143-9. PubMed ID: 9004358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia.
    Takeuchi H; Baba H; Maehara Y; Sugimachi K; Newman RA
    Cancer Chemother Pharmacol; 1996; 38(1):1-8. PubMed ID: 8603441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
    Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
    Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of bioreductive drugs in multicell spheroids.
    Durand RE; Olive PL
    Int J Radiat Oncol Biol Phys; 1992; 22(4):689-92. PubMed ID: 1544838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL
    Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia and acidity increase the cytotoxicity of mitomycin C and carboquone to human tumor cells in vitro.
    Kohnoe S; Emi Y; Takahashi I; Yoshida M; Maehara Y; Sugimachi K
    Anticancer Res; 1991; 11(4):1401-4. PubMed ID: 1746896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH; Siim BG; Evans JW; Brown JM
    Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
    Patterson AV; Robertson N; Houlbrook S; Stephens MA; Adams GE; Harris AL; Stratford IJ; Carmichael J
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):369-72. PubMed ID: 8195035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours.
    Phillips RM; Clayton MR
    Br J Cancer; 1997; 75(2):196-201. PubMed ID: 9010026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM; Lemmon MJ
    Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
    Lartigau E; Guichard M
    Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Alkylsulfonyloxy-3-hydroxy-1,4-naphthoquinones: a novel class of radio- and chemosensitizers of V79 cells.
    Hatzigrigoriou E; Papadopoulou MV; Shields D; Bloomer WD
    Oncol Res; 1993; 5(1):29-36. PubMed ID: 8369573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV; Bloomer WD
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL
    Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.